Zochling Jane
Menzies Research Institute, Private Bag 23, Hobart, Tasmania 7001, Australia.
Curr Opin Rheumatol. 2008 Jul;20(4):398-403. doi: 10.1097/BOR.0b013e3283028328.
To summarize the latest developments in outcome assessment and treatment in ankylosing spondylitis.
A number of clinical and radiological outcome measures used in the assessment of patients with ankylosing spondylitis have recently been critically reappraised and compared, to assist in the interpretation of study results and to guide choices for outcome measures in clinical trials. Clinical tools for assessing spinal mobility, peripheral joint disease and enthesitis, and radiograph and MRI scoring methods have been reviewed for validity and test performance in patients with ankylosing spondylitis. Experience with the use of anti-tumour necrosis factor-alpha therapies for ankylosing spondylitis continues to grow, and longer term data show these treatments continue to be effective and safe to 5 years of therapy.
As measurement tools for disease state and progression in ankylosing spondylitis are refined, the assessment of response to therapy improves, with the aim that real effect on structural damage in ankylosing spondylitis may be detected.
总结强直性脊柱炎疗效评估及治疗方面的最新进展。
近期对用于评估强直性脊柱炎患者的多项临床和放射学疗效指标进行了批判性重新评估和比较，以辅助解读研究结果并指导临床试验中疗效指标的选择。已对评估脊柱活动度、外周关节疾病和附着点炎的临床工具以及X线片和MRI评分方法在强直性脊柱炎患者中的有效性和测试性能进行了综述。使用抗肿瘤坏死因子-α疗法治疗强直性脊柱炎的经验不断积累，长期数据表明这些治疗在长达5年的治疗期内持续有效且安全。
随着强直性脊柱炎疾病状态和进展测量工具的完善，对治疗反应的评估得到改善，目标是能够检测出对强直性脊柱炎结构损伤的实际影响。
